

ALLOWANCE OF UNDERARM ADMINISTRATION PATENT IN UNITED STATES

Acrux (ASX: ACR) today confirmed that its patent application concerning the underarm administration of testosterone formulations has been allowed by the US Patent and Trademark Office (USPTO)¹. The patent is expected to grant following payment of the issue fee. The USPTO's preliminary calculation of patent term adjustment is one additional year beyond the expiry date of June 2026. This will be re-calculated when the patent grants.

A similar patent was previously granted in Australia, New Zealand, Singapore and South Africa and applications are under examination in a number of other countries around the world.

¹ The patent "Notice of Allowance" has not yet been mailed by the USPTO.

Contact

Jon Pilcher, CFO: 0438 422 271

About Acrux

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.
- Acrux has products marketed by licensees in the United States, approved in Europe, Canada and Australia and in registration or development.